Form 4: Veracyte CEO Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Veracyte's CEO, Marc Stapley, sold a total of 5,590 shares of common stock on December 13, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Marc Stapley, the CEO of Veracyte, Inc., executed sales of company stock on December 13, 2024.
- These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on September 13, 2024.
- A total of 5,190 shares were sold at a weighted average price of $43.3681, with individual sale prices ranging from $42.90 to $43.73.
- An additional 400 shares were sold at a weighted average price of $44.1413, with individual sale prices ranging from $44.03 to $44.33.
- Following these transactions, Mr. Stapley's direct holdings decreased to 307,345 shares.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock sales under a pre-arranged plan, which is neither positive nor negative. It is a neutral event.
Risks
- Executive stock sales can sometimes be perceived negatively by the market, potentially impacting investor sentiment.
Industry Context
Executive stock sales are a common practice, especially under pre-arranged trading plans like Rule 10b5-1, which allows insiders to sell shares without being accused of trading on non-public information. This is a routine disclosure and does not necessarily indicate a change in the company's outlook.
Comparison to Industry Standards
- Rule 10b5-1 plans are a standard practice among publicly traded companies, allowing executives to diversify their holdings while avoiding accusations of insider trading.
- The volume of shares sold by Mr. Stapley is relatively small compared to the total outstanding shares of Veracyte, and is not unusual for executive stock sales.
Stakeholder Impact
- The stock sales may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or financial position.
Key Dates
| Date | Description |
|---|---|
| 09/13/2024 | Date the Rule 10b5-1 trading plan was adopted by Marc Stapley. |
| 12/13/2024 | Date of the stock sales by Marc Stapley. |
| 12/17/2024 | Date the Form 4 was signed. |
Keywords
Veracyte, VCYT, Marc Stapley, stock sale, insider trading, Rule 10b5-1, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.